Chronic kidney disease represents an expanding public health challenge worldwide and across India. Clinicians increasingly recognize that ectopic fat accumulation directly compromises renal microvascular function and parenchymal integrity. Specifically, perirenal adipose tissue surrounds the kidneys within Gerota fascia and serves as an active endocrine organ. Emerging evidence indicates that this anatomical fat depot releases harmful adipokines and induces chronic localized inflammation. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists deliver proven organ-protective benefits. However, comparative evidence regarding how these modern drug classes modify perirenal adipose tissue remains sparse. The prospective ADIPO-CKD study provides compelling new insights into depot-specific cardiorenal adipose remodeling in patients with chronic kidney disease.

Understanding Perirenal Adipose Tissue in Renal Pathophysiology

Perirenal adipose tissue resides in close anatomical proximity to the renal fibrous capsule and hilum. Under physiological conditions, this specialized fat pad provides mechanical cushioning and maintains local thermal insulation. However, metabolic dysregulation rapidly transforms perirenal fat into a driver of progressive renal injury. In patients with metabolic syndrome or chronic kidney disease, adipocyte hypertrophy triggers local tissue hypoxia. Consequently, expanded perirenal adipocytes secrete high levels of pro-inflammatory mediators into adjacent vascular channels. These noxious molecules include tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1.

Furthermore, perirenal adipocytes release free fatty acids directly into the renal microcirculation. This phenomenon accelerates lipotoxicity within proximal tubular epithelial cells and podocytes. In addition, enlarged perirenal fat physically compresses the renal parenchyma and low-pressure arcuate veins. This compression increases interstitial hydrostatic pressure and reduces renal perfusion. Simultaneously, local activation of the renin-angiotensin-aldosterone system stimulates afferent arteriolar resistance and induces glomerular hyperfiltration. Therefore, perirenal adiposity accelerates glomerulosclerosis and tubular interstitial fibrosis. Clinicians must recognize that perirenal fat thickness serves as an independent marker of nephron decline. Managing this specific depot represents an essential frontier in comprehensive renal therapeutics.

The ADIPO-CKD Study Cohort and Diagnostic Methodology

The prospective ADIPO-CKD inception cohort evaluated structural adipose modifications in adults with chronic kidney disease stages 1 through 4. Investigators used standardized renal ultrasonography to measure bilateral perirenal adipose tissue thickness at baseline and after eight months. Specifically, sonographers measured the distance between the renal capsule and the inner surface of the abdominal wall. The mean of right and left measurements established the composite perirenal fat score. In addition, the research protocol evaluated epicardial adipose tissue thickness and overall body composition.

The study analyzed eighty patients who completed paired ultrasound evaluations across three distinct clinical groups. Thirty-two individuals received standard care without modern antidiabetic agents, serving as the reference control. Meanwhile, twenty-four patients received sodium-glucose cotransporter 2 inhibitors, and twenty-four patients received glucagon-like peptide 1 receptor agonist-based therapy. Patient body weights ranged broadly from 46 to 122 kilograms. Researchers utilized covariance analysis adjusted for baseline tissue thickness to evaluate longitudinal structural adaptations. Importantly, this rigorous design enabled researchers to isolate drug-specific anatomical effects from baseline variations. The study thus offers reliable prospective data on targeted organ-specific fat regression in renal disease.

Comparative Reductions in Perirenal Adipose Tissue Thickness

The ADIPO-CKD findings revealed striking differences between therapeutic regimens over the eight-month observation period. In the reference control group, perirenal adipose tissue thickness showed virtually no change (+0.035 cm, p = 0.376). This finding confirms that conventional kidney disease therapy does not alleviate ectopic retroperitoneal adiposity. In marked contrast, patients receiving sodium-glucose cotransporter 2 inhibitors demonstrated a significant reduction of 0.273 cm. This structural remodeling represented an impressive 20.4 percent decline from baseline (p = 0.0006).

Remarkably, patients receiving glucagon-like peptide 1 receptor agonist-based therapy achieved even greater anatomical reductions. In this therapeutic cohort, perirenal adipose tissue thickness decreased by 0.463 cm, reflecting a dramatic 36.2 percent decrease (p < 0.0001). Furthermore, covariance analysis demonstrated that both active treatment arms achieved statistically superior tissue clearance compared with controls. While SGLT2 inhibitors clearly reduced perirenal adiposity, GLP-1 receptor agonist therapy produced a visibly superior structural remodeling effect. These findings provide definitive quantitative proof that modern cardiorenal pharmacotherapies actively mobilize damaging fat depots adjacent to the kidneys.

Mechanisms Driving Ectopic Adipose Clearance in the Kidneys

The profound clearance of perirenal fat under modern pharmacotherapies involves distinct, multifaceted physiological mechanisms. Sodium-glucose cotransporter 2 inhibitors promote sustained urinary glucose excretion, creating a steady negative calorie balance. Consequently, this continuous caloric loss triggers systemic lipid mobilization and shifts cellular metabolism toward fatty acid oxidation. Furthermore, SGLT2 inhibitors attenuate systemic inflammation and downregulate sodium-hydrogen exchangers within renal tissues. As a result, these agents alleviate cellular nutrient overload and reduce ectopic fat infiltration around vital organs.

Conversely, glucagon-like peptide 1 receptor agonists exert potent neuroendocrine effects that suppress central appetite centers. Therefore, patients experience substantial caloric reduction, leading to systemic visceral fat loss. In addition, GLP-1 receptor agonists directly modulate peripheral adipocyte biology. Specifically, GLP-1 signaling enhances lipolysis in white adipose depots and stimulates thermogenic gene expression. Furthermore, these agents suppress macrophage infiltration and reduce vascular adhesion molecule expression in perivascular beds. Notably, the study investigated whether perirenal fat regression merely tracked total body weight reduction. While weight loss contributed significantly, the local regression of perirenal fat suggested specialized, depot-specific metabolic responsiveness to these incretin and gliflozin therapies.

Translating Findings to Clinical Practice in Chronic Kidney Disease

These compelling findings provide valuable practical guidance for nephrologists, endocrinologists, and general physicians managing complex cardiometabolic disease. In India, the convergence of type 2 diabetes, central adiposity, and chronic kidney disease imposes a tremendous clinical burden. Historically, clinicians evaluated renal therapeutic efficacy using systemic glycemic metrics, blood pressure, and albuminuria. However, these new observations highlight the crucial role of ectopic adipose depots in driving organ damage.

Therefore, selecting therapies that simultaneously address renal hemodynamics and ectopic fat accumulation offers clear strategic advantages. Sodium-glucose cotransporter 2 inhibitors maintain established benefits across glomerular filtration rates and heart failure outcomes. Similarly, glucagon-like peptide 1 receptor agonists deliver proven renal protection, marked albuminuria reduction, and superior body weight reduction. Combining these insights allows clinicians to tailor therapy for patients presenting with pronounced visceral adiposity and renal dysfunction. Clinicians can also utilize bedside renal ultrasound as a pragmatic, cost-effective monitoring tool to assess anatomical treatment response. Ultimately, targeting perirenal adipose tissue through contemporary pharmacotherapy represents an innovative step toward comprehensive cardiorenal risk reduction.

How does perirenal adipose tissue contribute to renal damage in chronic kidney disease?

Perirenal adipose tissue directly surrounds the renal parenchyma and vascular structures. When this depot expands pathologically, it exerts mechanical compression on the renal capsule and veins, raising intrarenal pressure. Furthermore, dysfunctional perirenal adipocytes secrete inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-6, directly into the local microcirculation. This localized paracrine signaling stimulates oxidative stress, promotes glomerular hyperfiltration, and triggers progressive renal interstitial fibrosis independent of systemic metabolic markers.

Why did GLP-1 receptor agonists produce greater perirenal fat reduction than SGLT2 inhibitors?

GLP-1 receptor agonists stimulate profound central appetite suppression and delay gastric emptying, leading to substantial overall caloric deficits. Consequently, these agents induce robust total fat mass loss, including visceral and retroperitoneal stores. In addition, GLP-1 receptor activation directly modulates adipocyte lipolysis and downregulates lipogenic gene transcription. While SGLT2 inhibitors facilitate caloric excretion through glycosuria and promote metabolic shifts, GLP-1-based regimens generally achieve greater absolute adipose volume reductions across diverse visceral fat compartments.

Can ultrasound measurement of perirenal fat guide nephroprotective pharmacotherapy in clinical practice?

Renal ultrasonography offers an accessible, non-invasive, and radiation-free tool to evaluate perirenal adipose thickness in routine clinical practice. Although clinicians currently monitor estimated glomerular filtration rate and urinary albumin excretion as primary therapeutic targets, serial perirenal fat assessments can provide valuable structural insights. Identifying significant ectopic adipose accumulation may help clinicians personalize metabolic therapy, optimize medication selection with modern cardiorenal agents, and track patient-specific tissue remodeling during long-term chronic kidney disease management.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Healthcare professionals should rely on their independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

Checa-Ros A et al. The Effects of GLP-1RA-Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD Patients. Diabetes Obes Metab. 2026 Oct 13. doi: 10.1111/dom.71441. PMID: 42865317.

Hammoud SH, AlZaim I, Al-Dhaheri Y, Eid AH, El-Yazbi AF. Perirenal Adipose Tissue Inflammation: Novel Insights Linking Metabolic Dysfunction to Renal Diseases. Front Endocrinol (Lausanne). 2021;12:707730. doi: 10.3389/fendo.2021.707730.

Cooper ME, van Raalte DH. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025;135(21):e194749. doi: 10.1172/JCI194749.

Chen X, Mao Y, Hu J, et al. Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes. Diabetes. 2021;70(10):2322-2332. doi: 10.2337/db20-1031.